Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Cuzick

Showing results (141-150 of 421) with videos related to

Pageof 43
Sort By:
British Journal of Cancer|January 26, 2021
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trialIvana Sestak, Glen Blake, Raj Patel, et al.
Gynecologic Oncology|January 8, 2014
Cervical excisional treatment of young women: a population-based studyWalter Kinney, William C Hunt, Helen Dinkelspiel, et al.
Sexually Transmitted Diseases|May 16, 2021
Burden of Mycoplasma genitalium and Bacterial Coinfections in a Population-Based Sample in New MexicoAnne Hammer, Patti E Gravitt, Rachael Adcock, et al.
Current Medical Research and Opinion|July 28, 2006
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancerAman Buzdar, Rowan Chlebowski, Jack Cuzick, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 28, 2006
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)Richard Eastell, Rosemary A Hannon, Jack Cuzick, et al.
Gastroenterology|May 8, 2004
Wide variation in adenoma detection rates at screening flexible sigmoidoscopyWendy Atkin, Pauline Rogers, Christopher Cardwell, et al.
Journal of Medical Imaging (Bellingham, Wash.)|February 18, 2020
External validation of a mammographic texture marker for breast cancer risk in a case-control studyChao Wang, Adam R Brentnall, James Mainprize, et al.
The Lancet. Oncology|September 5, 2008
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II)Valerie A Jenkins, Laurence M Ambroisine, Louise Atkins, et al.
The Lancet. Oncology|November 20, 2010
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialJack Cuzick, Ivana Sestak, Michael Baum, et al.
The Lancet. Oncology|December 16, 2014
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trialJack Cuzick, Ivana Sestak, Simon Cawthorn, et al.
Pageof 43

Showing results (141-150 of 421) with videos related to

Sort By:
Pageof 43
British Journal of Cancer|January 26, 2021
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trialIvana Sestak, Glen Blake, Raj Patel, et al.
Gynecologic Oncology|January 8, 2014
Cervical excisional treatment of young women: a population-based studyWalter Kinney, William C Hunt, Helen Dinkelspiel, et al.
Sexually Transmitted Diseases|May 16, 2021
Burden of Mycoplasma genitalium and Bacterial Coinfections in a Population-Based Sample in New MexicoAnne Hammer, Patti E Gravitt, Rachael Adcock, et al.
Current Medical Research and Opinion|July 28, 2006
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancerAman Buzdar, Rowan Chlebowski, Jack Cuzick, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 28, 2006
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)Richard Eastell, Rosemary A Hannon, Jack Cuzick, et al.
Gastroenterology|May 8, 2004
Wide variation in adenoma detection rates at screening flexible sigmoidoscopyWendy Atkin, Pauline Rogers, Christopher Cardwell, et al.
Journal of Medical Imaging (Bellingham, Wash.)|February 18, 2020
External validation of a mammographic texture marker for breast cancer risk in a case-control studyChao Wang, Adam R Brentnall, James Mainprize, et al.
The Lancet. Oncology|September 5, 2008
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II)Valerie A Jenkins, Laurence M Ambroisine, Louise Atkins, et al.
The Lancet. Oncology|November 20, 2010
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialJack Cuzick, Ivana Sestak, Michael Baum, et al.
The Lancet. Oncology|December 16, 2014
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trialJack Cuzick, Ivana Sestak, Simon Cawthorn, et al.
Pageof 43